BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Li J, Hou Y, Cai XB, Liu B. Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma. World J Gastroenterol 2016; 22(15): 4034-4040 [PMID: 27099447 DOI: 10.3748/wjg.v22.i15.4034]
URL: https://www.wjgnet.com/1007-9327/full/v22/i15/4034.htm
Number Citing Articles
1
Ao Huang, Xin-Rong Yang, Wen-Yuan Chung, Ashley R. Dennison, Jian Zhou. Targeted therapy for hepatocellular carcinomaSignal Transduction and Targeted Therapy 2020; 5(1) doi: 10.1038/s41392-020-00264-x
2
Lucia Cerrito, Brigida Eleonora Annicchiarico, Roberto Iezzi, Antonio Gasbarrini, Maurizio Pompili, Francesca Romana Ponziani. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiersWorld Journal of Gastroenterology 2019; 25(31): 4360-4382 doi: 10.3748/wjg.v25.i31.4360
3
Jian-Hong Zhong, Xue-Ke Du, Bang-De Xiang, Le-Qun Li. Adjuvant sorafenib in hepatocellular carcinoma: A cautionary comment of STORM trialWorld Journal of Hepatology 2016; 8(23): 957-960 doi: 10.4254/wjh.v8.i23.957
4
Han Ah Lee, Chai Hong Rim. Efficacy of Local Treatments for Hepatocellular Carcinoma Involving the Inferior Vena Cava and/or Right AtriumJournal of Hepatocellular Carcinoma 2020; : 435 doi: 10.2147/JHC.S285357
5
Jian Li, Wen-qiang Wang, Rong-hua Zhu, Xing Lv, Jin-lin Wang, Bin-yong Liang, Er-lei Zhang, Zhi-yong Huang. Postoperative adjuvant tyrosine kinase inhibitors combined with anti-PD-1 antibodies improves surgical outcomes for hepatocellular carcinoma with high-risk recurrent factorsFrontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1202039
6
Xu Feng, Guo-Ying Feng, Jie Tao, Yu-Pei Ao, Xin-Hua Wu, Shi-Guai Qi, Zheng-Rong Shi. Comparison of different adjuvant therapy regimen efficacies in patients with high risk of recurrence after radical resection of hepatocellular carcinomaJournal of Cancer Research and Clinical Oncology 2023; 149(12): 10505 doi: 10.1007/s00432-023-04874-0
7
Kuan-Chun Hsueh, Cheng-Chun Lee, Pi-Teh Huang, Chih-Yu Liang, Shun-Fa Yang. Survival Benefit of Experience of Liver Resection for Advanced Recurrent Hepatocellular Carcinoma Treated with Sorafenib: A Propensity Score Matching AnalysisCurrent Oncology 2023; 30(3): 3206 doi: 10.3390/curroncol30030243
8
Feng Che, Yi Wei, Qing Xu, Qian Li, Tong Zhang, Li-Ye Wang, Man Li, Fang Yuan, Bin Song. Noninvasive identification of SOX9 status using radiomics signatures may help construct personalized treatment strategy in hepatocellular carcinomaAbdominal Radiology 2024;  doi: 10.1007/s00261-024-04190-2
9
Kazuhiko Sakamoto, Hiroaki Nagano. Surgical treatment for advanced hepatocellular carcinoma with portal vein tumor thrombusHepatology Research 2017; 47(10): 957 doi: 10.1111/hepr.12923
10
Riccardo Nevola, Augusto Delle Femine, Valerio Rosato, Loreta Anesti Kondili, Maria Alfano, Davide Mastrocinque, Simona Imbriani, Pasquale Perillo, Domenico Beccia, Angela Villani, Rachele Ruocco, Livio Criscuolo, Marco La Montagna, Antonio Russo, Aldo Marrone, Ferdinando Carlo Sasso, Raffaele Marfella, Luca Rinaldi, Nicolino Esposito, Giuseppe Barberis, Ernesto Claar. Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era?Cancers 2023; 15(11): 2950 doi: 10.3390/cancers15112950
11
Wang Gu, Zhong Tong. Sorafenib in the treatment of patients with hepatocellular carcinoma (HCC) and microvascular infiltration: a systematic review and meta-analysisJournal of International Medical Research 2020; 48(8): 030006052094687 doi: 10.1177/0300060520946872
12
Lin Zheng, Chen-Yang Guo, Cheng-Shi Chen, Jin-Cheng Xiao, Hong-Tao Hu, Hong-Tao Cheng, Deng-Wei Zong, Li Jiang, Hai-Liang Li. Sorafenib improves lipiodol deposition in transarterial chemoembolization of Chinese patients with hepatocellular carcinoma: a long-term, retrospective studyOncotarget 2017; 8(57): 97613 doi: 10.18632/oncotarget.18811
13
Valentina Zanuso, Lorenza Rimassa, Chiara Braconi. The rapidly evolving landscape of HCC: Selecting the optimal systemic therapyHepatology 2023;  doi: 10.1097/HEP.0000000000000572
14
Masataka Amisaki, Hiroaki Saito, Naruo Tokuyasu, Teruhisa Sakamoto, Soichiro Honjo, Yoshiyuki Fujiwara. Prognostic value of postoperative complication for early recurrence after curative resection of hepatocellular carcinomaHepatobiliary & Pancreatic Diseases International 2018; 17(4): 323 doi: 10.1016/j.hbpd.2018.03.016
15
Lei Wang, Chunhong Xiao, Ren Wang, Jingbo Chen, Weiping Zhou, Jingfeng Liu, Nanping Lin, Kongying Lin. The Clinical Value of Postoperative Transarterial Chemoembolization for Resectable Patients with Intermediate Hepatocellular Carcinoma After Radical Hepatectomy: a Propensity Score-Matching StudyJournal of Gastrointestinal Surgery 2021; 25(5): 1172 doi: 10.1007/s11605-020-04588-5
16
Sha She, Jinzhi Shi, Jiling Zhu, Fan Yang, Jia Yu, Kai Dai. Impact of inflammation and the immune system on hepatocellular carcinoma recurrence after hepatectomyCancer Medicine 2024; 13(4) doi: 10.1002/cam4.7018
17
Han Ah Lee, Yeon Seok Seo, In-Soo Shin, Won Sup Yoon, Hye Yoon Lee, Chai Hong Rim. Efficacy and feasibility of surgery and external radiotherapy for hepatocellular carcinoma with portal invasion: A meta-analysisInternational Journal of Surgery 2022; 104: 106753 doi: 10.1016/j.ijsu.2022.106753
18
Qingli Li, Tianqiang Song. Association Between Adjuvant Sorafenib and the Prognosis of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical ResectionFrontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.633033
19
Hiroto Matsui Matsui, Shoichi Hazama, Masao Nakajima, Ming Xu, Satoshi Matsukuma, Yukio Tokumitsu, Yoshitaro Shindo, Shinobu Tomochika, Shin Yoshida, Michihisa Iida, Nobuaki Suzuki, Shigeru Takeda, Shigefumi Yoshino, Tomio Ueno, Masaaki Oka, Hiroaki Nagano. Novel adjuvant dendritic cell therapy with transfection of heat-shock protein 70 messenger RNA for patients with hepatocellular carcinoma: a phase I/II prospective randomized controlled clinical trialCancer Immunology, Immunotherapy 2021; 70(4): 945 doi: 10.1007/s00262-020-02737-y
20
Jianming Yang, Shijie Jiang, Yewu Chen, Jian Zhang, Yinan Deng. Adjuvant ICIs Plus Targeted Therapies Reduce HCC Recurrence after Hepatectomy in Patients with High Risk of RecurrenceCurrent Oncology 2023; 30(2): 1708 doi: 10.3390/curroncol30020132
21
G.K. Glantzounis, A. Paliouras, M.-C. Stylianidi, H. Milionis, P. Tzimas, D. Roukos, G. Pentheroudakis, E. Felekouras. The role of liver resection in the management of intermediate and advanced stage hepatocellular carcinoma. A systematic reviewEuropean Journal of Surgical Oncology 2018; 44(2): 195 doi: 10.1016/j.ejso.2017.11.022
22
Zun-Yi Zhang, Er-Lei Zhang, Bi-Xiang Zhang, Xiao-Ping Chen, Wei Zhang. Treatment for hepatocellular carcinoma with tumor thrombosis in the hepatic vein or inferior vena cava: A comprehensive reviewWorld Journal of Gastrointestinal Surgery 2021; 13(8): 796-805 doi: 10.4240/wjgs.v13.i8.796
23
Yifei Tan, Qing Xu, Zhenru Wu, Wei Zhang, Bo Li, Bohan Zhang, Xi Xu, Bo Zhang, Ke Yan, Jiulin Song, Tao Lv, Jian Yang, Li Jiang, Yujun Shi, Jiayin Yang, Lunan Yan. Overexpression of PD-L1 is an Independent Predictor for Recurrence in HCC Patients Who Receive Sorafenib Treatment After Surgical ResectionFrontiers in Oncology 2022; 11 doi: 10.3389/fonc.2021.783335
24
Wei Zhang, Bixiang Zhang, Xiao-ping Chen. Adjuvant treatment strategy after curative resection for hepatocellular carcinomaFrontiers of Medicine 2021; 15(2): 155 doi: 10.1007/s11684-021-0848-3
25
Zhi-Ming Zeng, Ning Mo, Jie Zeng, Fu-Chao Ma, Yan-Feng Jiang, Hua-Sheng Huang, Xi-Wen Liao, Guang-Zhi Zhu, Jie Ma, Tao Peng. Advances in postoperative adjuvant therapy for primary liver cancerWorld Journal of Gastrointestinal Oncology 2022; 14(9): 1604-1621 doi: 10.4251/wjgo.v14.i9.1604
26
Jin Shang, Shanling Xu, Jiaxing Zhang, Xuting Ran, Lang Bai, Hong Tang. Efficacy of sorafenib in patients with hepatocellular carcinoma after resection: a meta-analysisOncotarget 2017; 8(65): 109723 doi: 10.18632/oncotarget.21299
27
Bin Guo, Qian Chen, Zhicheng Liu, Xiaoping Chen, Peng Zhu. Adjuvant therapy following curative treatments for hepatocellular carcinoma: current dilemmas and prospectsFrontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1098958
28
Shenglan Huang, Dan Li, LingLing Zhuang, Liying Sun, Jianbing Wu. A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resectionWorld Journal of Surgical Oncology 2021; 19(1) doi: 10.1186/s12957-021-02280-9
29
Shashank Kumar, Abhay Kumar Pandey. Potential Molecular Targeted Therapy for Unresectable Hepatocellular CarcinomaCurrent Oncology 2023; 30(2): 1363 doi: 10.3390/curroncol30020105
30
Jiang Li, Fan Yang, Jian Li, Zhi-Yong Huang, Qi Cheng, Er-Lei Zhang. Postoperative adjuvant therapy for hepatocellular carcinoma with microvascular invasionWorld Journal of Gastrointestinal Surgery 2023; 15(1): 19-31 doi: 10.4240/wjgs.v15.i1.19
31
Sarwat Fatima, Nikki Pui-Yue Lee, Hiu Yee Kwan, Zhao Xiang Bian. Hepatocellular Carcinoma - Advances in Diagnosis and Treatment2018;  doi: 10.5772/intechopen.71480
32
Zun-Yi Zhang, Er-Lei Zhang, Bi-Xiang Zhang, Wei Zhang. Surgery for hepatocellular carcinoma with tumor thrombosis in inferior vena cava: A case reportWorld Journal of Clinical Cases 2021; 9(36): 11495-11503 doi: 10.12998/wjcc.v9.i36.11495
33
Chen Jue, Wu Zhifeng, Zhang Zhisheng, Cui Lin, Qian Yayun, Jin Feng, Gu Hao, Ishikawa Shintaro, Tadashi Hisamitsu, Guo Shiyu, Liu Yanqing. Vasculogenic mimicry in hepatocellular carcinoma contributes to portal vein invasionOncotarget 2016; 7(47): 77987 doi: 10.18632/oncotarget.12867
34
Chang-Zhi Chen, Jian-Hong Zhong, Ya-Peng Qi, Jie Zhang, Tao Huang, Liang Ma, Le-Qun Li, Tao Peng, Bang-De Xiang. Development of a preoperative prognostic scoring system to predict benefits of hepatic resection in advanced hepatocellular carcinoma patientsBioscience Reports 2021; 41(4) doi: 10.1042/BSR20201928
35
Zi-Wen Tao, Bao-Quan Cheng, Tao Zhou, Yan-Jing Gao. Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative reviewHepatobiliary & Pancreatic Diseases International 2022; 21(2): 134 doi: 10.1016/j.hbpd.2021.12.004